# Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

> **NCT01861236** · — · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 90 (actual)

## Conditions studied

- Advanced Hormone Dependent Prostate Cancer

## Interventions

- **DRUG:** Firmagon® (degarelix)

## Key facts

- **NCT ID:** NCT01861236
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2018-09-03
- **Final completion:** 2018-09-03
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01861236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01861236, "Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01861236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*